Galectin Therapeutics: Funding, Investors & Team (Oct 2026)
Galectin Therapeutics is applying its administration in galectin science and medication improvement to make new treatments for fibrotic illness and malignant growth. Drug competitors in light of the Company's remarkable starch innovation target galectin proteins which are key go betweens of biologic and pathologic capability. Galectin Therapeutics utilizes normally happening carb polymers with galactose deposits to make complex sugars with explicit atomic loads. Utilizing these novel starch based competitor intensifies that tight spot and repress galectin proteins, we are seeking after treatments for signs where galectins play a showed part in the pathogenesis of a specific illness. We center around sicknesses with serious, hazardous results to patients, and those where current therapy choices are restricted. Our methodology is to lay out clinical improvement moves toward that enhance the Company in the briefest time conceivable, and to look for accomplices as the program propels and requires a lot more noteworthy assets. Galectin Therapeutics influences broad logical and advancement ability as well as laid out associations with outside sources to accomplish savvy and productive turn of events. We are chasing after an unmistakable improvement pathway to clinical upgrade and commercialization for our lead intensifies in liver fibrosis and disease immunotherapy. Galectin Therapeutic stock is exchanged on the NASDAQ under the image GALT. The organization is situated in a suburb of Atlanta known as Norcross, Georgia USA
Galectin Therapeutics has raised $70.0M across 2 funding rounds on record, the most recent an undisclosed round of $10.0M announced in Jul 2025.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Galectin Therapeutics Company Profile and Key Stats
Latest funding round on record: Jul 2025.
Galectin Therapeutics Funding Rounds
Galectin Therapeutics raised $60.0M in a Post-IPO Debt announced in Jul 2022.
3 years later, an undisclosed round of $10.0M was announced in Jul 2025.
Galectin Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Galectin Therapeutics Funding Compared to Other Biotechnology Startups
Galectin Therapeutics' latest round of $10.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Galectin Therapeutics in Biotechnology and Norcross
Companies Similar to Galectin Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Galectin Therapeutics Funding FAQs
What does Galectin Therapeutics do?
Galectin Therapeutics is applying its administration in galectin science and medication improvement to make new treatments for fibrotic illness and malignant growth. Drug competitors in light of the Company's remarkable starch innovation target galectin proteins which are key go betweens of biologic and pathologic capability. Galectin Therapeutics utilizes normally happening carb polymers with galactose deposits to make complex sugars with explicit atomic loads. Utilizing these novel starch based competitor intensifies that tight spot and repress galectin proteins, we are seeking after treatments for signs where galectins play a showed part in the pathogenesis of a specific illness. We center around sicknesses with serious, hazardous results to patients, and those where current therapy choices are restricted. Our methodology is to lay out clinical improvement moves toward that enhance the Company in the briefest time conceivable, and to look for accomplices as the program propels and requires a lot more noteworthy assets. Galectin Therapeutics influences broad logical and advancement ability as well as laid out associations with outside sources to accomplish savvy and productive turn of events. We are chasing after an unmistakable improvement pathway to clinical upgrade and commercialization for our lead intensifies in liver fibrosis and disease immunotherapy. Galectin Therapeutic stock is exchanged on the NASDAQ under the image GALT. The organization is situated in a suburb of Atlanta known as Norcross, Georgia USA
How much funding has Galectin Therapeutics raised?
Galectin Therapeutics has raised $70.0M across 2 rounds on record. The most recent is an undisclosed round of $10.0M announced in Jul 2025.
When did Galectin Therapeutics last raise funding?
Galectin Therapeutics' most recent funding round on record is an undisclosed round of $10.0M, announced in Jul 2025.
Who founded Galectin Therapeutics?
FundedIQ lists James Czirr (Founder) at Galectin Therapeutics.
Where is Galectin Therapeutics headquartered?
Galectin Therapeutics is based in Norcross, Georgia, United States.
How many employees does Galectin Therapeutics have?
Galectin Therapeutics is in the 11-50 employee band.
How does Galectin Therapeutics' funding compare to other Biotechnology startups?
Galectin Therapeutics' latest round of $10.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Galectin Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Galectin Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.